Elsevier eBooks, Год журнала: 2023, Номер unknown, С. 141 - 153.e1
Опубликована: Май 11, 2023
Язык: Английский
Obesity Pillars, Год журнала: 2023, Номер 6, С. 100065 - 100065
Опубликована: Апрель 20, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of Artificial Intelligence, focused on the management patients with obesity.
Язык: Английский
Процитировано
68
Obesity Pillars, Год журнала: 2023, Номер 5, С. 100056 - 100056
Опубликована: Янв. 28, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.
Язык: Английский
Процитировано
32
Obesity Pillars, Год журнала: 2022, Номер 3, С. 100026 - 100026
Опубликована: Июль 5, 2022
Язык: Английский
Процитировано
35
Obesity Pillars, Год журнала: 2022, Номер 3, С. 100034 - 100034
Опубликована: Авг. 10, 2022
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of 30 common obesity myths, misunderstandings, and/or oversimplifications. The scientific support for this CPS based upon published citations, clinical perspectives OMA authors, and peer review by the leadership. discusses oversimplifications, utilizing referenced publications such as integrative use other CPSs help explain applicable physiology/pathophysiology. on oversimplifications one a series designed assist in care patients with disease obesity. Knowledge underlying science may medicine clinician improve
Язык: Английский
Процитировано
26
Obesity Pillars, Год журнала: 2023, Номер 8, С. 100092 - 100092
Опубликована: Окт. 19, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians with an overview on obesity, thrombosis, venous disease, lymphatic and lipedema.
Язык: Английский
Процитировано
13
Obesity Pillars, Год журнала: 2023, Номер 7, С. 100070 - 100070
Опубликована: Май 18, 2023
Язык: Английский
Процитировано
11
Obesity Pillars, Год журнала: 2025, Номер unknown, С. 100172 - 100172
Опубликована: Март 1, 2025
This collaboration from the Obesity Medicine Association (OMA) and American College of Osteopathic Family Physicians (ACOFP) examines obesity management a primary care perspective. joint perspective is based upon scientific evidence, clinical experience authors, peer review by OMA ACOFP leadership. The goal to identify answer sentinel questions about perspective, utilizing evidence-based publications, guided expert experience. disease that contributes both biomechanical complications most common cardiometabolic abnormalities encountered in care. Barriers impede optimal patients with include failure recognize as disease, lack accurate diagnosis, insufficient access treatment resources, inadequate training, time, adequate reimbursement adverse impact bias, stigma, discrimination. physicians are often first line healthcare setting. affords early intervention opportunities prevent and/or treat overweight obesity. Patient enhanced when clinicians risks benefits anti-obesity medications bariatric procedures, well long-term follow-up. Practical tools regarding 4 pillars nutrition therapy, physical activity, behavior modification, medical interventions (anti-obesity surgery) may assist improve health lives living
Язык: Английский
Процитировано
0
Obesity Pillars, Год журнала: 2022, Номер 3, С. 100025 - 100025
Опубликована: Июнь 23, 2022
Depression and chronic pain are two major non-communicable diseases (CNCD). Considering the bidirectional relationship between obesity CNCD, it is of utmost importance to understand effect medications utilized treat these on body weight. This a clinical review for depression We searched PubMed, Scopus, MEDLINE, Google Scholar databases studies topic from January 1, 1950 April 2022 in English language. Additionally, we present expert opinions fields obesity, pain, providing weight-centric approach pain. Several antidepressant associated with weight gain. Selective serotonin reuptake inhibitors, norepinephrine tricyclic antidepressants, monoamine oxidases, mirtazapine trazodone common antidepressants that can increase while bupropion significantly loss. Gabapentin pregabalin linked On other hand, topiramate significant Obesity, experts recommend avoiding if another effective alternative available. By shifting prescribing practices toward weight-conscious (i.e., switching gain loss/neutral), possible mitigate incidence drug-induced
Язык: Английский
Процитировано
16
Obesity Pillars, Год журнала: 2022, Номер 4, С. 100039 - 100039
Опубликована: Окт. 25, 2022
Historically, many anti-obesity medications (AOMs) were withdrawn from development and/or the market due to safety concerns. Another challenge was that, with some exceptions, most of these AOMs had limited weight reducing efficacy. Approved often did not meet reduction expectations either clinicians, or their patients. Currently, newer approved and investigational achieve greater than older AOMs. This has prompted an emerging new "too much loss" highly effective (heAOM) - something think possible prior year 2020.
Язык: Английский
Процитировано
16
Obesity Pillars, Год журнала: 2022, Номер 4, С. 100041 - 100041
Опубликована: Ноя. 4, 2022
Язык: Английский
Процитировано
14